ReCode Therapeutics

Home
United States
Menlo Park, CA
ReCode Therapeutics

ReCode Therapeutics is a clinical-stage genetic medicines company powering the future of genetic medicines with precision delivery.

11/25/2025

About 10% of the cystic fibrosis community does not benefit from currently available CFTR modulators. ReCode’s RCT2100 is an inhaled CFTR mRNA investigational therapy being studied in combination with ivacaftor to help lung cells produce functional CFTR protein. This study is evaluating safety, tolerability, and measures of lung function and respiratory health in people with CF who do not benefit from or are unable to take existing treatments.

Hear from Kors van der Ent, M.D., study investigator, and CF Patient Advocate Tim Wotton, in a conversation moderated by Dr. John Matthews, Chief Medical Officer at ReCode Therapeutics. The discussion will cover the purpose of the study, its methodology, and what participation entails for those interested in learning more.

Date: December 2
Session 1: 9:00 am PT / 12:00 pm ET
Session 2: 5:00 pm PT / 8:00 pm ET

Registration link in Bio!

11/17/2025

ReCode Therapeutics has initiated enrollment for our Phase 2 open-label clinical trial evaluating RCT2100 — our investigational inhaled CFTR mRNA therapy — in combination with ivacaftor for the treatment of cystic fibrosis (CF).

FDA clearance enables the study of RCT2100 + ivacaftor over a six-week treatment period in individuals with CF. U.S. clinical sites are now open for enrollment, with U.K. and EU sites expected to begin in Q1 2026.

Part 3 will assess safety and tolerability, with secondary measures that include lung function and quality of life. Together with data from other ongoing study cohorts, this work will help inform the future development strategy for RCT2100.

Formulated with our Selective Organ Targeting (SORT) LNP platform, RCT2100 is designed to deliver CFTR mRNA directly to the lungs to help address the underlying genetic cause of CF — particularly for those who do not benefit from approved CFTR modulators.

11/11/2025

This Veterans Day, we pause to honor and thank all who have served our nation. Your courage, commitment, and sacrifice continue to inspire us.

We are deeply grateful for your service.

11/06/2025

At ReCode, clinical development begins with understanding the patient journey. Priya Mitty Ryali, MBA, Head of Clinical Operations, explains how her team integrates innovation and compassion into every stage of RCT2100’s development — from at-home dosing options to patient concierge support.

These initiatives are designed to ease the clinical trial experience for people with CF and their families, while maintaining the highest standards of safety and rigor.

11/05/2025

Are you ready to help make a lasting impact in cystic fibrosis research? ReCode’s clinical study of RCT2100, an inhaled mRNA therapy, is designed for individuals with CF, and with convenient options like at-home dosing and travel accommodations, we’ve made participation as easy as possible. Your role could be the next step toward groundbreaking advancements in CF treatment.

The trial involves a brief screening, a structured treatment period, and a 24-week follow-up. Each visit offers an opportunity to advance CF research under the care of an expert medical team.

Visit the link in our bio to learn more.

10/29/2025

A Message from Shehnaaz Suliman, CEO of ReCode Therapeutics: I was honored to spend time with the CEO of the Mandela Rhodes Foundation, , discussing leadership lessons that stem from my experiences of fighting apartheid and how these have influenced my values and helped me set a strong leadership compass. We discussed the importance of innovation in enabling health equity for all, the potential for AI to democratize health access, and the importance of acting with courage when times are tough.

I see my job as a leader as not losing hope — as inspiring others, showing the way of the future, the possibility. The measure of a leader is not in comfort, but in showing resilience when the world seems to be pushing the hardest. That is the spirit of “Ubuntu” - the humanity that will endure. It is the recognition that what unites us is more powerful than what divides us. That takes courage, and courage does not have a gender or a color.

Thank you to the Äänit Prize and The Mandela Rhodes Foundation communities for creating space to reflect on these unifying values.

10/21/2025

As the field of cystic fibrosis continues to evolve, Priya Mitty Ryali, MBA, Head of Clinical Operations, sees reason for optimism — driven by collaboration, innovation, and an unwavering commitment to every patient still waiting for new options.

At , Priya and the ReCode team look forward to joining the broader CF community to discuss how ongoing research, including RCT2100, is helping to expand what’s possible in CF treatment and care.
As the field of cystic fibrosis continues to evolve, Mitty Ryali, MBA, Head of Clinical Operations, sees reason for optimism — driven by collaboration, innovation, and an unwavering commitment to every patient still waiting for new options.

At , Priya and the ReCode team look forward to joining the broader CF community to discuss how ongoing research, including RCT2100, is helping to expand what’s possible in CF treatment and care.

10/20/2025

After more than two decades leading breakthrough programs in cystic fibrosis, Heather Clark now drives ReCode’s CF strategy as Senior Vice President and Head of CF Franchise. Her focus remains on ensuring that every person with CF has access to effective therapies.

Here, Heather shares her perspective on RCT2100—our investigational inhaled mRNA therapy designed for individuals who currently have no benefit from approved CFTR modulators. Through targeted delivery, RCT2100 aims to restore CFTR function and expand treatment options for the CF community.

Connect with Heather and the ReCode team at and visit the link in our bio to learn more about our ongoing clinical study.

10/16/2025

We’re looking forward to attending the North American Cystic Fibrosis Conference ( ), taking place October 22–25 in Seattle. NACFC brings together the CF community, including families, clinicians, researchers, and industry, to accelerate progress in CF care and research.

Our team will be on-site to share updates on the progress of our ongoing Phase 2 study of RCT2100, an inhaled mRNA investigational therapy, and to connect with colleagues dedicated to advancing new treatment options. We’ll also host a Meet & Greet with investigators to discuss the study in more depth and explore opportunities to collaborate.

Using our Selective Organ Targeting (SORT) lipid nanoparticle platform, RCT2100 was designed to deliver CFTR mRNA directly to target cells in the lungs, instructing them to produce a functional version of the CFTR protein. By addressing the disease at its root cause, we are working toward meaningful progress for the CF community.

Interested in meeting with us during the conference? Visit us at Booth 607 or reach out to schedule time with our team via partnering@recodetx.com.

10/14/2025

On Indigenous Peoples’ Day, ReCode Therapeutics honors the rich histories, enduring cultures, and ongoing contributions of Indigenous communities.

We must also acknowledge the longstanding health disparities Indigenous peoples face, including limited care access and underrepresentation in medical research.

At ReCode, we believe true innovation in medicine must be equitable and inclusive. We are working to advance mRNA and gene correction therapies designed with precision and purpose by building clinical research programs that are shaped by, and accountable to, the communities we aim to serve.

10/01/2025

Clinical research for cystic fibrosis depends on the strength of the CF community. Every participant, caregiver, and healthcare provider plays a role in moving us forward. ReCode’s clinical study of an inhaled mRNA therapy is an opportunity to stand together in the fight against CF and build a brighter future for everyone affected.

Be a part of the future in CF treatment—learn more about our study at Cf-clinical-studies.com

Address

1140 O'Brien Drive
Menlo Park, CA
94025

Telephone

+14085851700

Website

https://recodetx.com/

Alerts

Be the first to know and let us send you an email when ReCode Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ReCode Therapeutics:

Shortcuts

Want your practice to be the top-listed Clinic in Menlo Park?